Peanut allergy: Biomolecular characterization for development of a peanut T-cell epitope peptide therapy

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

352Peanut (Arachis hypogaea) allergy is a growing problem globally carrying a huge socioeconomic burden for patients, families and the community. Studies suggest prevalence rates from 1-3% in many westernized countries with peanut allergy typically being a lifelong affliction (Nwaru et al. 2014, Osborne et al. 2011, Sicherer et al. 2003). Although fatalities are fortunately rare, the fear of death is very real for each patient. Currently, there is no cure for peanut allergy with management strategies focusing on complete avoidance and utilization of adrenaline as the emergency antidote for anaphylaxis following inadvertent exposure. There is a very strong imperative for a safe and effective specific therapy for peanut allergy.

Original languageEnglish
Title of host publicationFood Allergy
Subtitle of host publicationMolecular and Clinical Practice
EditorsAndreas L. Lopata
Place of PublicationBoca Raton FL USA
PublisherCRC Press
Chapter12
Pages351-372
Number of pages22
Edition1st
ISBN (Electronic)9781498722452
ISBN (Print)9781498722445
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • Food allergy
  • Peanut allergy
  • Peptide immuno therapy
  • Specific immunotherapy
  • SPIRE therapy
  • T-cell epitopes

Cite this

Rolland, J. M., Prickett, S. R., & O’Hehir, R. E. (2017). Peanut allergy: Biomolecular characterization for development of a peanut T-cell epitope peptide therapy. In A. L. Lopata (Ed.), Food Allergy: Molecular and Clinical Practice (1st ed., pp. 351-372). CRC Press. https://doi.org/10.1201/9781315120126